Celprogen Launches Cancer Stem Cells

Wed Jan 23, 2008 3:00pm EST

* Reuters is not responsible for the content in this press release.

SAN PEDRO, Calif.--(Business Wire)--Celprogen Inc., a leader in the Stem Cell Research and
Therapeutics industry for the development of stem cell technologies
for regenerative medicine, today announced that they have successfully
isolated and propagated 11 major cancer stem cells. These Cancer Stems
were launched in May 2007 at the AACR meeting in Los Angeles and also
in December 2007 at ASCB in Washington DC.

   Celprogen's cancer stem cells are available for basic science
research and drug discovery. The cancer stem cells are as follows:
Brain, Breast, Colon, Kidney, Leukemia, Liver, Lungs, Melanoma,
Ovarian, and Pancreatic & Prostate.

   Celprogen provides the Cancer Stem Cell Tissue culture system
which includes cells, pre-coated flasks with extracellular matrix and
Medium for growth and proliferation of these cells.

   About Celprogen Inc.

   Celprogen Inc. is a global Stem Cell Research & Therapeutics
company which is developing a proprietary portfolio of unique cancer
therapeutics products and life science research tools that includes
stem cell technologies for regenerative medicine, as well as
bio-engineering products for tissue & organ transplants. Headquartered
in San Pedro, California, Celprogen is committed to the research,
development, and manufacture of quality Stem Cell products to serve
our global community. Additional information about Celprogen is
available at http://www.celprogen.com.

Celprogen Inc.
Jay Sharma
Chief Executive Officer, Global Business Development

Copyright Business Wire 2008